Document Detail


The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients.
MedLine Citation:
PMID:  23091338     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Four recently approved drugs (cabazitaxel, sipuleucel-T, abiraterone, and denosumab), along with emerging therapies, bone-building therapies, hormonal treatments, and immunotherapies, have all demonstrated promise in advanced prostate cancer. It appears that the best outcomes will be achieved from the sequential use of multiple agents.
Authors:
Carole Alison Chrvala
Related Documents :
18393688 - Testing the h2o2-h2o hypothesis for life on mars with the tega instrument on the phoeni...
23410168 - Rationally designed multitarget anticancer agents.
24327718 - Targeting resistance in lung cancer.
14768518 - Fatal arrhythmia following intraoperative continuous hyperthermic peritoneal perfusion ...
23700898 - Expression of bmi-1 protein in cervical, breast and ovarian cancer.
21967738 - Platinum resistance in breast and ovarian cancer cell lines.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  P & T : a peer-reviewed journal for formulary management     Volume:  37     ISSN:  1052-1372     ISO Abbreviation:  P T     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-10-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9015516     Medline TA:  P T     Country:  United States    
Other Details:
Languages:  eng     Pagination:  453-63     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Don'T know much about health insurance exchanges: the next critical step: educating consumers and sm...
Next Document:  Adherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia: clinical and econ...